SCHEMBL18324840

SCHEMBL18324840

O=C(C1CC1)N1CCC(c2c[nH]c3cc(F)ccc23)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.65
DRD2 P14416 4/20 0.59
SLC6A4 P31645 2/20 0.59
ADRA1D P25100 3/20 0.57
HTR2A P28223 3/20 0.52
HTR7 P34969 3/20 0.52
KCNH2 Q12809 3/20 0.52
CCR2 P41597 1/20 0.52
KDM4E B2RXH2 1/20 0.51
BRD4 O60885 1/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
CREBBP Q92793 1/20 0.51
OPRM1 P35372 1/20 0.51
OPRL1 P41146 1/20 0.51
SPR P35270 1/20 0.49
ADRA1B P35368 1/20 0.49
HTR1D P28221 1/20 0.48
HTR1B P28222 1/20 0.48
HTR1A P08908 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21758792 0.92 HSD11B1 (0.60) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL18324848 0.89 HSD11B1 (0.57) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL18324838 0.88 HSD11B1 (0.55) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL6184605 0.88 DRD2 (0.61) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL16802074 0.86 KDM4E (0.69) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL18324842 0.86 DRD2 (0.66) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL18324845 0.84 DRD2 (0.61) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL18324833 0.84 DRD2 (0.58) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL18701706 0.84 DRD2 (0.61) HSD11B1DRD2SLC6A4ADRA1DHTR2A
SCHEMBL18324841 0.83 DRD2 (0.60) HSD11B1DRD2SLC6A4ADRA1DHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3082802-B1 TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE IOMET PHARMA LTD (GB) 2020-02-26 EP disclosed
US-9931347-B2 Pharmaceutical compound IOMET PHARMA LTD. (US) 2018-04-03 US disclosed
US-9931347-B2 Pharmaceutical compound IOMET PHARMA LTD. (US) 2018-04-03 US disclosed
US-20160367564-A1 Pharmaceutical Compound IOMET PHARMA LTD. (GB) 2016-12-22 US disclosed
US-20160367564-A1 Pharmaceutical Compound IOMET PHARMA LTD. (GB) 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160367564-A1 Pharmaceutical Compound TDO2, IDO1, IDO2 HSD11B1 783/4885DRD2 447/4885SLC6A4 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.